vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Citizens Community Bancorp Inc. (CZWI). Click either name above to swap in a different company.

Citizens Community Bancorp Inc. is the larger business by last-quarter revenue ($15.8M vs $13.5M, roughly 1.2× Assertio Holdings, Inc.). On growth, Citizens Community Bancorp Inc. posted the faster year-over-year revenue change (14.9% vs -57.9%). Over the past eight quarters, Citizens Community Bancorp Inc.'s revenue compounded faster (1.9% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.

ASRT vs CZWI — Head-to-Head

Bigger by revenue
CZWI
CZWI
1.2× larger
CZWI
$15.8M
$13.5M
ASRT
Growing faster (revenue YoY)
CZWI
CZWI
+72.8% gap
CZWI
14.9%
-57.9%
ASRT
Faster 2-yr revenue CAGR
CZWI
CZWI
Annualised
CZWI
1.9%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
CZWI
CZWI
Revenue
$13.5M
$15.8M
Net Profit
$4.3M
Gross Margin
Operating Margin
-86.7%
31.0%
Net Margin
27.1%
Revenue YoY
-57.9%
14.9%
Net Profit YoY
58.1%
EPS (diluted)
$-4.54
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
CZWI
CZWI
Q4 25
$13.5M
$15.8M
Q3 25
$49.5M
$16.2M
Q2 25
$29.2M
$16.1M
Q1 25
$26.5M
$14.2M
Q4 24
$32.2M
$13.7M
Q3 24
$29.2M
$14.2M
Q2 24
$31.1M
$13.5M
Q1 24
$32.4M
$15.2M
Net Profit
ASRT
ASRT
CZWI
CZWI
Q4 25
$4.3M
Q3 25
$11.4M
$3.7M
Q2 25
$-16.4M
$3.3M
Q1 25
$-13.5M
$3.2M
Q4 24
$2.7M
Q3 24
$-2.9M
$3.3M
Q2 24
$-3.7M
$3.7M
Q1 24
$-4.5M
$4.1M
Operating Margin
ASRT
ASRT
CZWI
CZWI
Q4 25
-86.7%
31.0%
Q3 25
23.2%
27.9%
Q2 25
-27.5%
25.1%
Q1 25
-50.0%
28.0%
Q4 24
-41.9%
24.5%
Q3 24
-10.4%
29.5%
Q2 24
-11.6%
35.0%
Q1 24
-13.4%
34.2%
Net Margin
ASRT
ASRT
CZWI
CZWI
Q4 25
27.1%
Q3 25
23.1%
22.7%
Q2 25
-56.0%
20.3%
Q1 25
-51.1%
22.5%
Q4 24
19.7%
Q3 24
-10.0%
23.1%
Q2 24
-11.8%
27.2%
Q1 24
-13.9%
26.9%
EPS (diluted)
ASRT
ASRT
CZWI
CZWI
Q4 25
$-4.54
$0.44
Q3 25
$0.11
$0.37
Q2 25
$-0.17
$0.33
Q1 25
$-0.14
$0.32
Q4 24
$-3.28
$0.28
Q3 24
$-0.03
$0.32
Q2 24
$-0.04
$0.35
Q1 24
$-0.05
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
CZWI
CZWI
Cash + ST InvestmentsLiquidity on hand
$63.4M
$118.9M
Total DebtLower is stronger
$51.8M
Stockholders' EquityBook value
$94.0M
$187.9M
Total Assets
$267.0M
$1.8B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
CZWI
CZWI
Q4 25
$63.4M
$118.9M
Q3 25
$93.4M
$82.4M
Q2 25
$98.2M
$67.5M
Q1 25
$87.3M
$100.2M
Q4 24
$100.1M
$50.2M
Q3 24
$88.6M
$36.6M
Q2 24
$88.4M
$36.9M
Q1 24
$80.7M
$28.6M
Total Debt
ASRT
ASRT
CZWI
CZWI
Q4 25
$51.8M
Q3 25
Q2 25
Q1 25
Q4 24
$66.6M
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
CZWI
CZWI
Q4 25
$94.0M
$187.9M
Q3 25
$105.8M
$186.8M
Q2 25
$93.3M
$183.5M
Q1 25
$108.5M
$180.1M
Q4 24
$121.1M
$179.1M
Q3 24
$130.5M
$180.1M
Q2 24
$132.2M
$176.0M
Q1 24
$134.5M
$172.8M
Total Assets
ASRT
ASRT
CZWI
CZWI
Q4 25
$267.0M
$1.8B
Q3 25
$319.8M
$1.7B
Q2 25
$273.8M
$1.7B
Q1 25
$286.4M
$1.8B
Q4 24
$284.7M
$1.7B
Q3 24
$276.0M
$1.8B
Q2 24
$279.4M
$1.8B
Q1 24
$282.0M
$1.8B
Debt / Equity
ASRT
ASRT
CZWI
CZWI
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
0.37×
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
CZWI
CZWI
Operating Cash FlowLast quarter
$-30.0M
$11.7M
Free Cash FlowOCF − Capex
$10.4M
FCF MarginFCF / Revenue
65.9%
Capex IntensityCapex / Revenue
8.3%
Cash ConversionOCF / Net Profit
2.74×
TTM Free Cash FlowTrailing 4 quarters
$17.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
CZWI
CZWI
Q4 25
$-30.0M
$11.7M
Q3 25
$-4.8M
$6.6M
Q2 25
$19.1M
$-406.0K
Q1 25
$-12.5M
$1.6M
Q4 24
$11.5M
$20.4M
Q3 24
$-35.0K
$3.5M
Q2 24
$7.4M
$5.1M
Q1 24
$7.5M
$9.1M
Free Cash Flow
ASRT
ASRT
CZWI
CZWI
Q4 25
$10.4M
Q3 25
$6.2M
Q2 25
$-632.0K
Q1 25
$1.5M
Q4 24
$19.5M
Q3 24
$3.4M
Q2 24
$4.8M
Q1 24
$8.9M
FCF Margin
ASRT
ASRT
CZWI
CZWI
Q4 25
65.9%
Q3 25
38.4%
Q2 25
-3.9%
Q1 25
10.7%
Q4 24
142.2%
Q3 24
23.8%
Q2 24
35.7%
Q1 24
58.9%
Capex Intensity
ASRT
ASRT
CZWI
CZWI
Q4 25
8.3%
Q3 25
2.4%
Q2 25
1.4%
Q1 25
0.7%
Q4 24
6.5%
Q3 24
0.0%
0.9%
Q2 24
2.3%
Q1 24
1.4%
Cash Conversion
ASRT
ASRT
CZWI
CZWI
Q4 25
2.74×
Q3 25
-0.42×
1.80×
Q2 25
-0.12×
Q1 25
0.50×
Q4 24
7.55×
Q3 24
1.07×
Q2 24
1.39×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

CZWI
CZWI

Segment breakdown not available.

Related Comparisons